T he glucose analog, 18 F-fluorodeoxyglucose ( 18 F-FDG), is one of the most frequently used radiopharmaceuticals in clinical practice, especially in the fields of cancer and inflammatory diseases. 1, 2 Recently, preclinical and clinical studies have highlighted a potential role of 18 F-FDG positron-emission tomography coupled with computed tomography (PET/CT) imaging in the diagnostic management of suspected acute allograft rejection (AR) in kidney transplant recipients (KTRs). [3] [4] [5] The rationale for such an original application of 18 F-FDG PET/CT relies on the AR-associated recruitment of activated leukocytes into the transplant. 6, 7 Activated leukocytes are indeed characterized by a high metabolic activity and increased uptake of 18 F-FDG, which can be measured using PET/CT.
Renal AR represents the main reversible cause of renal dysfunction in KTR. 8 In current clinical practice, AR diagnosis ultimately depends on renal transplant needle biopsy (on the basis of Banff histological classification 7 ) . However, such an invasive procedure is associated with a significant risk of bleeding and graft loss and is limited by sampling error and/or interobserver variability. 9, 10 Therefore, other more sensitive and less invasive modalities, including omic analyses of biofluids and in vivo imaging, are under investigation. 5, 8, [11] [12] [13] Hence, experimental rodent models of allogeneic kidney transplantation have demonstrated that 18 F-FDG PET/CT noninvasively, specifically, and early detect renal AR. 4, 14 In man, a pilot series showed a 100% negative predictive value of 18 F-FDG PET/CT in excluding AR in KTR with renal dysfunction. 3 Furthermore, the accumulation of 18 F-FDG in kidney transplant positively correlated with leukocyte infiltration conventionally assessed by Banff score. 7 Although supporting a role for 18 F-FDG PET/CT imaging in AR diagnosis, these data question the impact of renal function per se on 18 F-FDG uptake by kidney allograft. In rats, the renal clearance of 18 F-FDG does not correlate with renal function. 4 In man, the available literature is poor with regard to the impact of kidney dysfunction on renal 18 F-FDG uptake. 15 Such a surprising gap of knowledge prompted us to perform the present study investigating correlations between renal function and kidney allograft 18 F-FDG uptake and in a retrospective cohort of KTR.
PATIENTS AND METHODS

Patients
Adult KTR who underwent at least one 18 F-FDG PET/CT between January 2010 and December 2015 were retrospectively identified using a computerized billing database. Patients with documented AR or pyelonephritis, as well as patients under chronic hemodialysis, were excluded. Medical files were systematically reviewed. The cohort was subdivided into 5 conventional groups according to CKD stages upon CKD-EPI-based eGFR 16 : stage 1, greater than 90 mL/min per 1.73 m 2 ; stage 2, 60 to 89 mL/min per 1.73 m 2 ; stage 3a, 45-59 mL/min per 1.73 m 2 ; stage 3b, 30-44 mL/min per 1.73 m 2 ; and stage 4, 15-29 mL/min per 1.73 m 2 . The study was approved by the institutional ethics committee. 18 
F-FDG PET/CT Imaging
PET/CT procedure used cross-calibrated Philips GEMINI TF Big Bore or TF 16 PET/CT systems (Philips Medical Systems, Cleveland, OH). A low-dose helical CTwas performed (5-mm slice thickness, 120-kV tube voltage, and 40-mAs tube current-time product), followed by a PETemission scanning with 2 bed positions each lasting 240 seconds. Image reconstruction applied iterative list mode time-of-flight algorithms. Corrections for attenuation, deadtime, random, and scatter events were applied. PET/CT images were independently read and quantified by 2 experienced nuclear medicine physicians blinded. Mean SUV were measured in each VOI (renal allograft, aorta, liver, and psoas) using the following formula:
Statistics
Data were expressed as mean ± 1 standard deviation (SD). One-way analysis of variance (ANOVA) and Spearman rank correlation coefficient were calculated upon CKD stages, with P < 0.05 considered as statistically significant (MedCalc, Mariakerke, Belgium).
RESULTS
Eighty-two adult KTRs underwent at least one 18 F-FDG PET/CT for tumor staging (n = 46), fever of unknown origin (n = 25), or suspected infection (n = 11), between January 2010 and December 2015. The clinical and biological characteristics of the whole cohort are summarized in Table 1 . The mean age of our cohort was 58 ± 13 years, with an averaged body mass index of 24.5 ± 4.8 kg/m 2 and male-to-female ratio of 1.4. The cohort was subdivided into 5 conventional groups according to renal function assessed by estimated glomerular filtration rate (eGFR) upon chronic kidney disease (CKD)-EPI equation, 16 which resulted in CKD stage 1 (n = 3), stage 2 (n = 21), stage 3a (n = 20), stage 3b (n = 29), and stage 4 (n = 9). No statistically significant differences were found among groups concerning recipient's characteristics, donor's status, types of kidney transplantation, and immunosuppression at the time of 18 F-FDG PET/CT imaging (Table 1) .
PET/CT was performed at 67 ± 15 minutes after intravenous injection of a mean dose of 3.7 ± 0.6 MBq/Kg BW (0.1 mCi) of 18 F-FDG. Mean glycemia was 113 ± 34 mg/dL. 18 F-FDG PET/CT imaging was performed in fasting conditions without administration of diuretics. Four volumes of interest (VOIs) of 1 mL were drawn in the cortical region of both upper (n = 2) and lower (n = 2) poles of the renal transplant, at distance from the pelvicalyceal zone ( Fig. 1 ). Additionally, VOIs were drawn in the descending thoracic aorta (5 mL), liver (13 mL), and left psoas muscle (5 mL), classically regarded as regions of baseline activity. Mean standard uptake values (SUVmean) were measured in each VOI, with no threshold activity. Mean kidney, aorta, liver, and psoas SUVmean were BMI indicates body mass index; KTx, kidney transplantation; LD, living donor; DCD, donor after circulatory death; DBD, donor after brain death; PRA, panel reactive antibody; MDRD eGFR, estimated glomerular filtration rate according to "modification of diet in renal disease" formula; CNI, calcineurin inhibitor; CsA, cyclosporin A; FK, tacrolimus; MMF, mycophenolate mofetyl; MPA, mycophenolic acid; Aza, azathioprine; mTOR, mammalian target of rapamycin. Data are expressed as mean ± 1 standard deviation and as median (min-max). *Wilcoxon Rank test.
1.8 ± 0.2, 1.7 ± 0.3, 2.1 ± 0.4, and 0.7 ± 0.2, respectively. Considering the whole cohort, no significant correlation was observed between eGFR and kidney (r, 0.12; P, 0.28) SUV mean ( Fig. 2A) nor between eGFR and aorta (r, −0.14; P, 0.20), liver (r, −0.09; P, 0.41), or psoas muscle (r, 0.21; P, 0.07) SUVmean (Fig. 3) . Considering CKD subgroups, ANOVA showed no difference of kidney SUVmean (P, 0.62) between CKD stages (Fig. 2B) . Likewise, no difference was observed in aorta (P, 0.85), liver (P, 0.91), or psoas muscle (P, 0.66) SUVmean among CKD stages (Fig. 4) . Finally, mean coefficient of variation (CV) of kidney SUVmean was calculated on the basis of greater than 3 consecutive 
DISCUSSION
In the kidney, the glucose analog 18 F-FDG is freely filtered through glomeruli, incompletely reabsorbed by proximal tubule cells and shed into the urine. 17 Because CKD is characterized by impaired glomerular filtration and reduced glucose metabolism, 18 one might expect that CKD would affect 18 F-FDG distribution and uptake in renal and extrarenal tissues. Still, rodent studies showed that the renal clearance of 18 F-FDG does not correlate with renal function. 4 In man, Minamimoto et al found no significant difference in native kidney, liver, and muscle SUVmean between 20 healthy volunteers and 20 patients with suspected renal failure. 15 Similarly, no significant correlation was observed between eGFR and 18 F-FDG distribution and uptake within an hour postinjection in our present series of 82 KTRs. Furthermore, intraindividual variability of kidney graft SUVmean resides within the 10% to 15% range of previously reported CV in various normal and tumoral tissues. 19, 20 Besides its retrospective design, one main limitation of our present study may be the interference of urinary 18 F-FDG signal on the quantification of 18 F-FDG accumulation in the renal parenchyma. 21 To overcome this problem, we drew multiple independent 3D VOI in renal allograft cortex, right beneath the capsule at distance from the urinary pelvis. A mean value of SUV was measured in each VOI, which further help attenuate pixel variations of maximum SUV within one given VOI. 18 F-FDG PET/CT imaging is routinely performed in KTRs in various clinical settings, including detection and staging of posttransplant lymphoproliferative diseases 22 or infections. 23 The advantages of 18 F-FDG PET/CTare rapid imaging, high target-to-background ratio, and a direct coregistration with low-dose CT without radiologic contrast medium administration. 1 It can be used safely in patients with renal function ranging from normal to mildly reduced GFR to ESRD. Conversely, renal function per se does not seem to significantly influence 18 F-FDG uptake and distribution in kidney, liver, or muscles, as illustrated here. Such an absence of correlation between eGFR and liver SUVmean in KTR gives novel and essential information, especially regarding cancer and posttransplant lymphoproliferative disease follow-up. Indeed, response to chemotherapy is classically assessed on the basis of a 5-point scale (also known as Deauville criteria) using the liver as reference organ. 24 Lesions that have 18 F-FDG uptake ≤ liver (Deauville scores 1, 2, or 3) are metabolically negative, whereas lesions that have FDG uptake > liver (Deauville scores 4 or 5) are positive. 25 Given the combined increased incidences of lymphoproliferative disorders and CKD in KTR, one first needs to establish that liver 18 F-FDG accumulation is independent of renal function before applying Deauville scoring to KTR. 26 Our present data may provide a key answer to this question. Regarding the persistence of 18 F-FDG in the vascular compartment at 60 minutes postinjection, no significant difference was found between CKD stages. Our quantifications were performed using 3D VOI of the arterial blood pool. Such approach may explain previous contradictory reports based on 2D regions of interest drawn in the venous pool. 27 Note that assessing blood pool SUVmean remains problematic, given the influence of various factors, including PET/CT timing, blood cell density, or blood flow. 28 In conclusion, the uptake of 18 F-FDG by renal allograft within an hour postinjection is not significantly impacted by CKD. Such important information may help interpret 18 F-FDG PET/CT images in various clinical settings, including noninvasive diagnosis of AR in KTR. 
